Skip to Content

Angiochem Presents Complete Phase 1 /2 Clinical Data for ANG1005: Further Demonstrating Benefits of Targeting LRP-1 Pathway in Cancer

-- Improved Time to Disease Progression and Stabilization of Disease Observed --

-- Brain Cancer Data Presented At 2010 American Society of Clinical Oncology Annual Meeting --

MONTREAL--(BUSINESS WIRE)--Jun 7, 2010 - Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL. These data demonstrated that by targeting the lipoprotein receptor-related protein (LRP-1), which is highly expressed on the surface of the blood-brain barrier (BBB) and upregulated on malignant cancer cells. Angiochem's novel anticancer agent, ANG1005, gained entry into the brain and penetrated tumor cells to provide increased time to disease progression, significant reductions in tumor size and reversal of neurological deficits caused by tumor intrusion.

“These very encouraging results observed in the ANG1005 Phase 1/2 clinical studies clearly support further development of ANG1005 in both malignant gliomas and brain metastases, two brain cancers for which patients face a dismal prognosis with few treatment options,” said Jan Drappatz, MD, Center for Neuro-Oncology at Dana-Farber Cancer Institute, Department of Neurology at Brigham and Women's Hospital, and, Harvard Medical School, and ANG 1005 lead investigator for Boston-area study centers.

ANG1005 Results in Glioblastoma Study:

In this Phase 1/2 study, 18 of the 63 patients received ANG1005 at 650 mg/m2, the maximum tolerated dose (MTD) and recommended highest Phase 2 dose. Disease control (‰¥ stable disease (SD) by MacDonald criteria) was achieved in 17 of 28 patients (61%) dosed ‰¥300 mg/m2, including two complete responses and two partial responses. In this group the median time to progression was 32 weeks in responders (‰¥ SD) and 7 weeks in all treated patients. No evidence of CNS toxicity (measured by neurological and neurocognitive testing) or no antibody production was found. Therapeutic concentrations of ANG1005 were found in tumor tissue extracted from patients (n=7) who had received ANG1005 prior to surgery. Additional analysis revealed that tumor tissue samples did not grow when placed in culture.

ANG1005 Results in Brain Metastases Study:

In this Phase 1/2 study, 20 of the 56 patients received ANG1005 at 650 mg/m2. Overall disease control (‰¥ SD by RECIST criteria) was achieved in 71% of patients dosed ‰¥ 420mg/m2, including 10 patients who failed prior taxane therapy. Partial responses were observed in five patients at MTD: two patients with breast cancer, two with non-small cell lung cancer, and one with ovarian cancer. Important reductions in the size of cancer tumors were also achieved in metastases located in organs outside of brain including the liver, lung and lymph nodes. Median time to progression was 18 weeks in responders (‰¥ SD) and 8 weeks in all patients.

“Angiochem's LRP-1 targeting technology platform (EPiC) has the potential to transform targeted cell-killing cancer therapies , to a new level of effectiveness for the treatment of brain cancers, by enabling penetration of the drug through the BBB and overcoming multi-drug resistance mechanisms,” said Jean-Paul Castaigne, MD, President and CEO of Angiochem. “In total these data confirm that targeting the LRP-1 receptor validates Angiochem's product-generating platform for the development of novel cancer therapies.”

About ANG1005 // ANG1005 has a novel mode of action, targeting the lipoprotein receptor-related protein (LRP-1) pathway. ANG1005 was created with the Engineered Peptide Compounds (EPiC) platform which leverages the LRP-1 mediated pathway. Studies have shown that ANG1005 gains entry into the brain by targeting LRP-1, one of the most highly expressed receptors on the surface of the BBB. ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including gliomas, Breast , Lung, Liver and Ovarian cancers.

About Angiochem // Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases and to target the cancer cells. Angiochem's lead product candidate, ANG1005 completed two separate clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit

Copyright 2010 Angiochem, Inc.

Contact: The Yates Network
Gina Nugent, 617-460-3579



Posted: June 2010